Brett Whatcott, DO
Interventional Pain Medicine · Fort Smith, ARNPI 1134169816
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,302 of the $9,507 with a category attached, or 66.3%. Medtronic accounts for 65.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $4,313 and has fallen 98.6% since, to $59 in 2025.
Across 151 payments — averaging $62.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$481
- Tersera Therapeutics LLC$199
- Collegium Pharmaceutical, Inc.$161
- Eisai Inc.$144
- plus $424 from 11 others
What the payments were for
- Travel & lodging$6,30266%
- Food & beverage$3,20534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 56 | $6,210 |
| Abbott | 18 | $1,888 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $481 |
| Tersera Therapeutics LLC | 9 | $199 |
| Collegium Pharmaceutical, Inc. | 8 | $161 |
| Eisai Inc. | 13 | $144 |
| Biodelivery Sciences International, Inc. | 5 | $130 |
| Amgen | 3 | $54 |
| Boston Scientific | 1 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Pfizer | 2 | $33 |
| GRT US Holding, Inc. | 3 | $32 |
| Averitas Pharma Inc. | 1 | $19 |
| Saluda Medical Americas, Inc. | 1 | $17 |
| Vertos Medical, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Kinex Medical Company LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$2,850
- PROCLAIM$1,636
- INTELLIS ADAPTIVESTIM$1,171
- KYPHON Balloon Kyphoplasty$576
- KYPHON EXPRESS II KYPHOPAK TRAY$300
How this compares
$9,507 in reported general payments places this provider in the 85th percentile of 29 interventional pain medicine providers in Arkansas.
See all interventional pain medicine providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 30 | $73,611 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,347 | $42,692 |
| BelbucaBuprenorphine Hcl | 45 | $30,536 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 499 | $16,703 |
| Oxycodone Hcl | 520 | $8,460 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $5,543 |
| Buprenorphine | 16 | $4,232 |
| Xtampza ErOxycodone Myristate | 13 | $3,799 |
| Tizanidine Hcl | 298 | $3,535 |
| Pregabalin | 175 | $3,443 |
| Gabapentin | 291 | $3,402 |
| Lidocaine | 26 | $2,712 |
| Cyclobenzaprine Hcl | 249 | $2,691 |
| Ondansetron OdtOndansetron | 74 | $2,558 |
| Fentanyl | 16 | $1,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $481 | $73,61130 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $161 | $34,33558 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 interventional pain medicine providers in Arkansas.
Other interventional pain medicine in Fort Smith
- Mohammad EldeebFort Smith$9K
- Thomas de MirandaFort Smith$4K
- Sameer JainBryant$56K
- Ryan KrafftMountain Home$51K
- Robert CannonFayetteville$15K
- Amir QureshiLittle Rock$14K
- Ahmed GhalebLittle Rock$7K
- Michael AdamsMena$6K
- Majid SaleemLittle Rock$5K
- Gary FrankowskiLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.